This is an article that talks about four health care stocks that might lose a lot of value soon. The author uses something called RSI, which helps figure out if a stock is too expensive or not. If the RSI is above 70, it means the stock could be in trouble. Read from source...

- The article title is misleading and sensationalized. It implies that the four health care stocks mentioned are guaranteed to crash this quarter, which is not supported by any evidence or analysis in the text. A more accurate title would be something like "Some Health Care Stocks Show Signs of Overbought Conditions".
- The article uses an outdated and unreliable momentum indicator, the RSI, without explaining its limitations or how it can be improved. For example, the RSI does not account for volume or volatility, which are important factors in stock price movement. It also assumes that higher prices always mean more strength and lower prices always mean less strength, which is not necessarily true in all market conditions. A better alternative would be to use a more advanced momentum indicator like the MACD or the stochastic oscillator, or to combine technical analysis with fundamental analysis for a more holistic view of stock performance.
- The article focuses too much on PepGen Inc., which is not even one of the four stocks mentioned in the subheading. This creates confusion and distracts from the main topic of the article. It also implies that PepGen Inc.'s clinical trial results are more important than those of the other three stocks, which may not be true or supported by facts. A more balanced and informative approach would be to provide equal attention and analysis to all four stocks, and to clearly indicate why PepGen Inc. is relevant to the overall theme of the article.
- The article does not provide any concrete reasons or evidence for why the four stocks may crash this quarter. It simply states that they are overbought according to the RSI, but does not explain how or why this condition may lead to a decline in price. It also does not consider other factors that may influence the performance of these stocks, such as market trends, sector news, earnings reports, insider activity, analyst ratings, etc. A more thorough and convincing article would be to present a well-researched and data-driven argument for why the four stocks are likely to underperform their peers or the market in general.

{main points}

- Four stocks in the health care sector are overbought according to the RSI indicator, which measures momentum and short-term performance.
- These stocks are PepGen Inc., Athenex Inc., Guardion Health Sciences Inc., and Cidara Therapeutics Inc.
- Overbought stocks tend to be more vulnerable to price declines and may crash in the near future.
- Investors who value momentum as a key criterion should avoid these stocks or sell their positions if they already own them.
- Alternatively, short sellers could benefit from betting against these stocks, assuming the risks of a potential rebound or regulatory change.